Health
Anakinra shows therapeutic potential in critically ill COVID-19 patients – News-Medical.Net
A team of international scientists recently conducted an open-level clinical trial to investigate the effects of personalized immunotherapy on critically ill COVID-19…
A team of international scientists recently conducted an open-level clinical trial to investigate the effects of personalized immunotherapy on critically ill coronavirus disease 2019 (COVID-19) patients. Their findings suggest that treatment with an interleukin-1 (IL-1) receptor antagonist, anakinra, can improve the clinical output of severe COVID-19 patients. The study is currently available on the medRxiv* preprint server.
Background
Since the emergence of the COVID-19 pandemic caused by severe…
-
Noosa News13 hours agoMassive wind farm project in Queensland axed amid community backlash
-
Business16 hours agoIAG shares are racing higher today. Here’s why
-
Noosa News14 hours agoProp Allan Alaalatoa returns to the Wallabies line-up for Rugby Championship game against Argentina
-
General18 hours agoQueensland government dumps Forest Wind project